Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)
Hong Kong
· Delayed Price · Currency is HKD 4.440
+0.040 (0.91%)
Apr 24, 2025, 4:08 PM HKT
HKG:9989 Revenue
In the year 2024, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.26B CNY, down -3.43%. Shenzhen Hepalink Pharmaceutical Group had revenue of 1.19B in the quarter ending December 31, 2024, a decrease of -13.91%.
Revenue
5.26B CNY
Revenue Growth
-3.43%
P/S Ratio
2.79
Revenue / Employee
2.73M CNY
Employees
1,926
Market Cap
15.59B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.26B | -186.65M | -3.43% |
| Dec 31, 2023 | 5.45B | -1.71B | -23.94% |
| Jan 1, 2023 | 7.16B | 794.23M | 12.48% |
| Jan 1, 2022 | 6.37B | 1.03B | 19.38% |
| Dec 31, 2020 | 5.33B | 707.42M | 15.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| Sino Biopharmaceutical | 30.72B |